Delivery strategies in treatments of leukemia

Ci, Tianyuan; Zhang, Wentao; Qiao, Yingyu; Li, Huangjuan; Zang, Jing; Li, Hongjun; Feng, Nianping; Gu, Zhen

doi:10.1039/d1cs00755f

Cited by 24 publications

(14 citation statements)

References 263 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to their high binding affinity and specificity, along with some superior advantages compared to functional antibodies, aptamers have emerged as excellent alternatives to antibodies in the diagnosis and treatment of hematologic disorders. Therefore, various therapeutic targets for hematologic malignancies, including important targets such as CD33, CXCL12, and P-selectin, , are being investigated with aptamer-based drugs or aptamer-conjugated drugs in preclinical or clinical stages.…”

Section: Current Status and Challenges Of Rna Therapeutics In Clinicsmentioning

confidence: 99%

Chemically Modified Platforms for Better RNA Therapeutics

Shi,

Zhen,

Zhang

et al. 2024

Chem. Rev.

View full text Add to dashboard Cite

RNA-based therapies have catalyzed a revolutionary transformation in the biomedical landscape, offering unprecedented potential in disease prevention and treatment. However, despite their remarkable achievements, these therapies encounter substantial challenges including low stability, susceptibility to degradation by nucleases, and a prominent negative charge, thereby hindering further development. Chemically modified platforms have emerged as a strategic innovation, focusing on precise alterations either on the RNA moieties or their associated delivery vectors. This comprehensive review delves into these platforms, underscoring their significance in augmenting the performance and translational prospects of RNA-based therapeutics. It encompasses an in-depth analysis of various chemically modified delivery platforms that have been instrumental in propelling RNA therapeutics toward clinical utility. Moreover, the review scrutinizes the rationale behind diverse chemical modification techniques aiming at optimizing the therapeutic efficacy of RNA molecules, thereby facilitating robust disease management. Recent empirical studies corroborating the efficacy enhancement of RNA therapeutics through chemical modifications are highlighted. Conclusively, we offer profound insights into the transformative impact of chemical modifications on RNA drugs and delineates prospective trajectories for their future development and clinical integration. CONTENTS1. Introduction 930 2. Current Status and Challenges of RNA Therapeutics in Clinics 933 2.1. Molecular Mechanisms and Clinical Research Progress of RNAs 934 2.1.1. ASO 934 2.1.2. siRNA 934 2.1.3. Aptamer 936 2.1.4. mRNA 936 2.1.5. RNA Therapeutics on the Cusp of Clinical Breakthroughs 938 2.2. Major Challenges of Current RNA Therapeutics in Clinics 940 2.

show abstract

Section: Current Status and Challenges Of Rna Therapeutics In Clinicsmentioning

confidence: 99%

Chemically Modified Platforms for Better RNA Therapeutics

Shi,

Zhen,

Zhang

et al. 2024

Chem. Rev.

View full text Add to dashboard Cite

show abstract

“…Leukemia is a hematopoietic system disease caused by the abnormal proliferation, enhanced self-renewal ability, blocked differentiation, and reduced apoptosis of leukemic cells caused by hematopoietic cell mutations [ 1 ]. Leukemia accounts for 2.8% of all new cancer cases and 3.4% of new cancer deaths [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Research Progress on the Use of Metformin in Leukemia Treatment

Wang,

Wei

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementMetformin is a first-line drug in the clinical treatment of type 2 diabetes. Its main molecular mechanism involves the activation of adenosine 5′-monophosphate-activated protein kinase (AMPK), which regulates cell energy metabolism. Many clinical studies have shown that metformin can reduce the incidence and mortality of cancer in patients with or without diabetes. In vitro studies also confirmed that metformin can inhibit proliferation, promote apoptosis, and enhance the response of cells to chemical drugs and other anticancer effects on a variety of leukemia cells. In recent years, leukemia has become one of the most common malignant diseases. Although great progress has been made in therapeutic approaches for leukemia, novel drugs and better treatments are still needed to improve the therapeutic efficacy of these treatments. This article reviews the application status and possible mechanism of metformin in the treatment of leukemia to further understand the anticancer mechanism of metformin and expand its clinical application.

show abstract

“…Recent progress in materials science, nanotechnology, and biomedicine have enabled the development of diverse nanomaterial-based drug delivery systems, including conjugated drugs, liposomes, nanoparticles, and cell-derived platforms. − These nanomaterials offer several key advantages for tumor treatment compared to traditional methods. First, nanomaterials can leverage the enhanced permeability and retention (EPR) effect to accumulate and be selectively retained within tumor tissues. − Second, nanomaterial surfaces can be facilely functionalized with proteins, peptides, and biomolecules to enhance targeting precision. − Third, nanomaterials provide protection for encapsulated drugs, genes, and therapeutic agents, shielding them from degradation in physiologically complex microenvironments .…”

Section: Introductionmentioning

confidence: 99%

Sniping Cancer Stem Cells with Nanomaterials

Wang,

Guo,

Yang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

Delivery strategies in treatments of leukemia

Abstract: This review highlights the advances of delivery strategies in leukemia treatment via modifying drug pharmacokinetics, navigating drugs to the tumor cell/microenvironment and reversing drug resistance. Challenges and possible opportunities are discussed.

Cited by 24 publications

References 263 publications

Chemically Modified Platforms for Better RNA Therapeutics

Chemically Modified Platforms for Better RNA Therapeutics

Research Progress on the Use of Metformin in Leukemia Treatment

Sniping Cancer Stem Cells with Nanomaterials

Contact Info

Product

Resources

About